Atossa Genetics (NASDAQ:ATOS) Releases Earnings Results, Beats Expectations By $0.09 EPS

Atossa Genetics (NASDAQ:ATOS) issued its earnings results on Friday. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.09, FiscalAI reports.

Atossa Genetics Trading Down 2.5%

ATOS traded down $0.06 during trading on Friday, hitting $2.36. The company’s stock had a trading volume of 77,520 shares, compared to its average volume of 66,253. Atossa Genetics has a twelve month low of $1.70 and a twelve month high of $19.35. The business’s fifty day simple moving average is $2.62 and its 200 day simple moving average is $4.51. The firm has a market capitalization of $20.32 million, a price-to-earnings ratio of -0.74 and a beta of 1.29.

Analyst Ratings Changes

Several equities research analysts have commented on ATOS shares. Rodman & Renshaw began coverage on Atossa Genetics in a research report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, Ascendiant Capital Markets lowered their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.33.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Atossa Genetics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after acquiring an additional 37,809 shares during the period. Qube Research & Technologies Ltd lifted its holdings in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares in the last quarter. Jane Street Group LLC purchased a new position in Atossa Genetics during the second quarter valued at $381,000. Ameriprise Financial Inc. acquired a new stake in shares of Atossa Genetics in the second quarter valued at about $2,468,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Atossa Genetics in the second quarter valued at about $26,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.